Powering the Immune System to Transform Lives
Our Pipeline
A Deep, Broad Pipeline to Address Unmet Patient Need
Our deep and broad pipeline contains multiple clinical-stage and preclinical candidates for diseases with significant unmet patient need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world.
Hepatitis Delta
elebsiran + tobevibart1,2
- Goal:
- Treatment
- Phase:
- Phase 3,75%
Learn more about our therapeutic focus on Hepatitis Delta
Solid Tumors
VIR-5500 (PSMA)3,4 ± ARPI or ± taxane
- Goal:
- Treatment
- Phase:
- Phase 1,75%
VIR-5818 (HER2)3 ± pembrolizumab
- Goal:
- Treatment
- Phase:
- Phase 1,75%
VIR-5525 (EGFR)3 ± pembrolizumab
- Goal:
- Treatment
- Phase:
- Phase 1,75%
Undisclosed PRO-XTEN® TCE targets5
- Goal:
- Treatment
- Phase:
- Pre-clinical,75%
Learn more about our therapeutic focus on Oncology
HIV Cure
Preclinical antibody candidates
- Collaborator:
- Gates Foundation
- Goal:
- Treatment
- Phase:
- Pre-clinical,75%
Learn more about our therapeutic focus on HIV
1 Tobevibart incorporates Xencor’s Xtend™ and other Fc technologies
2 Norgine holds exclusive license for the commercial rights to the combination of elebsiran and tobevibart in Europe, Australia and New Zealand. Brii Biosciences retains rights to the combination in the Greater China Territory (People’s Republic of China, Hong Kong, Taiwan and Macau).
3 Masked TCEs licensed from Sanofi
4 Astellas holds co-development and co-commercialization rights for VIR-5500 for the treatment of prostate cancer
5 Vir Biotechnology has exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.